Article
NICE tells Gilead to cut Trodelvy's price and rejects eczema meds from AbbVie, Pfizer and Leo
Rating:
0.0
Views:
81
Likes:
1
Library:
1
It was a thumbs-down week for the U.K.'s drug price watchdog. | In draft guidance, NICE has rejected Gilead Sciences' Trodelvy for use against triple negative breast cancer, saying it is too expensive for use by the NHS. And in a separate decision, NICE has shot down three atopic dermatitis drugs—AbbVie's Rinvoq, Pfizer's Cibinqo and Leo Pharma's Adtralza.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value